AI-generated analysis. Always verify with the original filing.
Innate Pharma S.A. reported full year 2025 financial results with revenue and other income of €9.0 million, operating expenses of €63.0 million, and net loss of €49.2 million. Cash position stood at €44.8 million as of December 31, 2025, with runway until end of Q3 2026, alongside pipeline updates including planned lacutamab Phase 3 initiation in H2 2026 subject to financing.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Revenue and other income | $9.0K | |
| Research and development | $43.6K | |
| Selling, general and administrative | $19.4K | |
| Total operating expenses | $63.0K | |
| Operating income (loss) | $-54.0K | |
| Net income (loss) | $-49.2K | |
| Basic income (loss) per share | $-0.55 |